AgaMatrix and Glytec said today that the companies are partnering to develop a cloud-based diabetes management platform to optimize clinical access to glucose data and insulin titration support. The platform will combine AgaMatrix’s FDA-cleared Jazz Wireless 2 Bluetooth blood glucose monitoring tech with Glytec’s eGlycemic Management System, according to the companies. Get the full story […]
Pharmaceutical
Bigfoot buys connected insulin pen tech
Artificial pancreas developer Bigfoot Biomedical said today that it acquired Patients Pending and its connected insulin pen technology for an undisclosed amount. With this acquisition, Bigfoot said it is the 1st company to simultaneously pursue both insulin infusion and injection delivery solutions. Get the full story at our sister site, Drug Delivery Business News.
Bristol-Myers Squibb launches prefilled syringe option for arthritis drug
Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for moderately to severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old. The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home. Get the full story at our sister site, Drug Delivery Business […]
Mylan defends chairman to shareholder advisory firm amid scrutiny
Mylan (NSDQ:MYL) defended chairman Robert Coury to Institutional Shareholder Services, an shareholder advisory group, earlier this week as the firm prepares to release a report advising shareholders how they should vote in the upcoming re-election of Coury and other directors. Major investors like the New York City and State pension funds have urged shareholders to vote against […]
Clearside Biomedical highlights interim data from retreatment trial
Clearside Biomedical (NSDQ:CLSD) touted preliminary data from a non-interventional and retrospective trial of patients who participated in the completed Phase II trial of CLS-TA for suprachoroidal administration. Clearside’s formulation of triamcinolone acetonide, in combination with intravitreally administered Eylea, was evaluated as a treatment for macular edema associated with retinal vein occlusion. Get the full story […]
Novocure launches Optune, chemotherapy combo trial for glioblastoma
Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients […]
InCarda touts inhaled flecainide as paroxysmal atrial fibrillation therapy
InCarda Therapeutics touted top-line data today from a Phase I study of its InRhythm inhaled flecainide as a treatment of symptomatic acute episodes of paroxysmal atrial fibrillation. InRhythm delivers flecainide via inhalation to get the drug to the heart through the lungs. Flecainide is already approved as an oral anti-arrhythmic drug for patients with PAF. […]
Kentucky doc gets jail time for bad opioid prescription habits & Medicaid fraud
Dr. George Kudmani, an OB/GYN from Kentucky, was sentenced to 4 years in prison this week after a federal jury ruled that he was guilty of inappropriately doling out opioids and Medcaid fraud. The jury found Kudmani guilty of 19 counts of unlawful distribution of controlled substances and 8 counts of health care fraud. After Kudmani serves his […]
Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]
Glytec highlights hospital cost-savings for insulin therapy
At the 6th International Hospital Diabetes meeting, Glytec‘s eGlycemic Management System was featured in several studies demonstrating the products’s ability to save hospitals money. One case study presented at the meeting described a health system that adopted Glytec’s eGlycemic Management System and saw 1st-year cost savings of $7.5 million. Get the full story at our sister […]
Express Scripts, CVS sued over Mylan’s EpiPen
Express Scripts (NSDQ:ESRX) and CVS Health (NYSE:CVS) were among the pharmacy benefit managers named in a lawsuit last week, when a potential class of patients accused them of violating the Employee Retirement Income Security Act by failing to negotiate lower prices for Mylan’s EpiPen allergy auto-injector. The suit, filed in the Minnesota District Court, alleges that […]